We are live on ! Find out more
CRBP icon

Corbus Pharmaceuticals
CRBP

86 hedge funds and large institutions have $55.4M invested in Corbus Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 24 increasing their positions, 24 reducing their positions, and 29 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 24

4.63% less ownership

Funds ownership: 89.92% → 85.29% (-4.6%)

13% less funds holding

Funds holding: 99 → 86 (-13)

45% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 29

56% less call options, than puts

Call options by funds: $58K | Put options by funds: $132K

57% less capital invested

Capital invested by funds: $129M → $55.4M (-$73.9M)

Holders
86
Holders Change
-13
Holders Change %
-13.13%
% of All Funds
1.15%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
16
Increased
24
Reduced
24
Closed
29
Calls
$58K
Puts
$132K
Net Calls
-$74K
Net Calls Change
-$5.87M

Top Buyers

Rank Fund Capital Flow
1
PM
Prosight Management
Texas
+$2.69M
2
EAM
Exome Asset Management
New York
+$2.56M
3
Renaissance Technologies
Renaissance Technologies
New York
+$1.82M
4
Comerica Bank
Comerica Bank
Texas
+$1.77M
5
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$1.68M

Top Sellers

Rank Fund Capital Flow
1
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$6.24M
2
ACM
Altium Capital Management
New York
-$4.54M
3
Millennium Management
Millennium Management
New York
-$2.52M
4
VC
Vivo Capital
California
-$1.97M
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$1.95M
Name Holding Trade Value Shares
Change 		Change in
Stake
CAM
1
Cormorant Asset Management
Massachusetts
$12.6M – – –
O
2
OrbiMed
New York
$6.22M – – –
OCA
3
Octagon Capital Advisors
New York
$5.92M – – –
BlackRock
4
BlackRock
New York
$4.49M -$241K -27,312 -3%
Vanguard Group
5
Vanguard Group
Pennsylvania
$3.57M +$113K +12,855 +2%
PM
6
Prosight Management
Texas
$3.05M +$2.69M +305,136 +113%
Renaissance Technologies
7
Renaissance Technologies
New York
$1.83M +$1.82M +206,100 +148%
EAM
8
Exome Asset Management
New York
$1.54M +$2.56M +289,690 New
Geode Capital Management
9
Geode Capital Management
Massachusetts
$1.44M +$70.5K +7,982 +3%
AC
10
Armistice Capital
New York
$1.33M +$124K +14,000 +6%
State Street
11
State Street
Massachusetts
$1.19M -$45.3K -5,130 -2%
Comerica Bank
12
Comerica Bank
Texas
$1.06M +$1.77M +200,000 +20,000,000%
Acadian Asset Management
13
Acadian Asset Management
Massachusetts
$1.01M +$1.68M +190,093 New
Mirae Asset Global ETFs Holdings
14
Mirae Asset Global ETFs Holdings
Hong Kong
$685K -$299K -33,919 -21%
TCM
15
Tang Capital Management
California
$677K -$1.02M -115,133 -47%
Two Sigma Investments
16
Two Sigma Investments
New York
$643K -$115K -13,011 -10%
AQR Capital Management
17
AQR Capital Management
Connecticut
$573K +$953K +107,983 New
Millennium Management
18
Millennium Management
New York
$540K -$2.52M -285,046 -74%
Northern Trust
19
Northern Trust
Illinois
$530K -$29.8K -3,381 -3%
HP
20
HealthInvest Partners
Sweden
$522K – – –
Citadel Advisors
21
Citadel Advisors
Florida
$494K +$821K +92,991 New
UBS Group
22
UBS Group
Switzerland
$482K +$12.9K +1,467 +2%
Charles Schwab
23
Charles Schwab
California
$470K -$82.6K -9,357 -10%
PCM
24
Prelude Capital Management
New York
$427K +$709K +80,347 New
Morgan Stanley
25
Morgan Stanley
New York
$407K +$132K +14,980 +24%
1
2 3 4 5

CRBP Hedge Fund Activity: Q1 2025 in Review

86 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Corbus Pharmaceuticals (CRBP) for Q1 2025, worth a combined $55.4M — down 57% from $129M a quarter earlier.

Sellers outnumbered buyers: 29 funds closed out of CRBP and 16 opened new positions — a net loss of 13 holders — while 24 trimmed existing stakes and 24 added.

The largest buyer was Prosight Management, adding an estimated $2.69M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $6.24M sold.

  • 86 institutional investors held Corbus Pharmaceuticals (CRBP) as of Q1 2025, down from 99 in Q4 2024.
  • Funds reported $55.4M of Corbus Pharmaceuticals stock for Q1 2025, down 57% quarter-over-quarter.
  • 16 funds opened new Corbus Pharmaceuticals positions in Q1 2025 and 29 closed out, a net change of -13 holders.
  • The largest Corbus Pharmaceuticals buyer in Q1 2025 was Prosight Management, an estimated $2.69M added.
  • The largest Corbus Pharmaceuticals seller in Q1 2025 was Adage Capital Partners, an estimated $6.24M sold.

Based on aggregated 13F filings for Q1 2025.